Chinese drug regulator National Medical Products Administration handed down a certificate to Shanghai Pharmaceuticals Holding (SHA:601607, HKG:2607) for the registration of its lurasidone hydrochloride tablets, according to the company's disclosure on the Shanghai Stock Exchange.
The pharmaceutical company is allowed to market the drug as a treatment for schizophrenia, the Tuesday disclosure added.
Shares of the company fell more than 1% in recent trade.
Price (HKD): $19.40, Change: $+0.09, Percent Change: +0.47%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments